Surmodics | SRDX - Des Atouts





Des Atouts Changement Date
Abbott USD 86.71B 2.53B 2025-12
Align Technology USD 6.23B 141K 2025-12
Anika Therapeutics USD 190.27M 833K 2025-12
Arrowhead Research USD 1.6B 218.89M 2025-12
Artivion USD 884.8M 27.13M 2025-12
Baxter International USD 20.06B 1.01B 2025-12
Boston Scientific USD 43.67B 966M 2025-12
EDAP TMS EUR 61.46M 6.88M 2025-09
Edwards Lifesciences USD 13.27B 216.5M 2025-09
Haemonetics USD 2.49B 48.73M 2025-12
Heron Therapeutics USD 255.88M 6.93M 2025-12
J&J USD 199.21B 6.39B 2025-12
Merit Medical Systems USD 2.69B 54.92M 2025-12
Mesa Laboratories USD 434.85M 4.5M 2025-12
Nektar Therapeutics USD 280.41M 20.94M 2025-12
Option Care Health USD 3.46B 24.08M 2025-12
Stryker USD 47.84B 787M 2025-12
Surmodics USD 169.82M 8.74M 2025-06
Trinity Biotech USD 103.71M 4.08M 2025-09